Video

Roswell Park Offers Exclusive CAR T-Cell Clinical Trial for Patients with Advanced or Metastatic Hepatoma

 A new, first-in-humans clinical trial for hepatocellular carcinoma uses an “armored” CAR T-cell therapy designed to resist the hostile tumor microenvironment found in 77% of patients with this disease.

News

Join Roswell Park Revolutionaries for Cell Therapy Symposium at ASH

Renier Brentjens, MD, PhD, and Marco Davila, MD, PhD, will host a satellite symposium during this year’s ASH meeting to discuss the evolving landscape of CAR T-cell therapy.

News

Risk vs. Benefit: Clinical Trial Aims to Identify Patients with Early-Stage NSCLC Who May Not Need Immunotherapy After Surgery

Many patients with early-stage non-small cell lung cancer (NSCLC) are treated post-surgery with the monoclonal antibody durvalumab (brand name Imfinzi) — an FDA-approved regimen.

News

RP1 Oncolytic Therapy Provides New Hope for Patients Whose Melanoma Resists Conventional Immunotherapy

About half of all patients with advanced melanoma face a poor prognosis because their cancer doesn’t respond to immunotherapy — but results of a recent clinical trial show that an unusual treatment strategy could change that.

News

Myeloma Experts Uncover Key Role for Neutrophils, Potential New Treatment Strategy

Research shows that blocking CXCR2 receptor reduced tumor growth and improved survival; clinical trial underway.

News

Single Dose of Radiation as Effective as 5-Week Course for Lung Cancer: Roswell Park Shares Results at ASTRO

Dr. Mark Farrugia describes new approach to post-operative radiation therapy for non-small cell lung cancer